(红斑狼疮)。

IF 0.7
Patrick-Pascal Strunz, Marc Schmalzing, Matthias Goebeler, Astrid Schmieder
{"title":"(红斑狼疮)。","authors":"Patrick-Pascal Strunz, Marc Schmalzing, Matthias Goebeler, Astrid Schmieder","doi":"10.1007/s00105-025-05554-5","DOIUrl":null,"url":null,"abstract":"<p><p>Cutaneous lupus erythematosus (CLE) comprises a heterogeneous spectrum of autoimmune dermatoses. Four main forms are distinguished: acute (ACLE), subacute (SCLE), intermediate (ICLE), and chronic CLE (CCLE). Epidemiological studies show that the overall risk of developing systemic lupus erythematosus (SLE) is highest within the first 3 years following diagnosis of CLE. Therefore, patients with newly diagnosed CLE should be closely monitored for systemic symptoms, especially in the first few years following CLE diagnosis. Therapy of CLE includes both topical and systemic approaches. Treatment of SLE with organ and cutaneous manifestation should ideally be treated in close cooperation with an internal medicine rheumatologist. The overall therapeutic landscape of lupus erythematosus in increasingly moving toward personalized approaches.</p>","PeriodicalId":72786,"journal":{"name":"Dermatologie (Heidelberg, Germany)","volume":" ","pages":"582-600"},"PeriodicalIF":0.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Lupus erythematosus].\",\"authors\":\"Patrick-Pascal Strunz, Marc Schmalzing, Matthias Goebeler, Astrid Schmieder\",\"doi\":\"10.1007/s00105-025-05554-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cutaneous lupus erythematosus (CLE) comprises a heterogeneous spectrum of autoimmune dermatoses. Four main forms are distinguished: acute (ACLE), subacute (SCLE), intermediate (ICLE), and chronic CLE (CCLE). Epidemiological studies show that the overall risk of developing systemic lupus erythematosus (SLE) is highest within the first 3 years following diagnosis of CLE. Therefore, patients with newly diagnosed CLE should be closely monitored for systemic symptoms, especially in the first few years following CLE diagnosis. Therapy of CLE includes both topical and systemic approaches. Treatment of SLE with organ and cutaneous manifestation should ideally be treated in close cooperation with an internal medicine rheumatologist. The overall therapeutic landscape of lupus erythematosus in increasingly moving toward personalized approaches.</p>\",\"PeriodicalId\":72786,\"journal\":{\"name\":\"Dermatologie (Heidelberg, Germany)\",\"volume\":\" \",\"pages\":\"582-600\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatologie (Heidelberg, Germany)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s00105-025-05554-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologie (Heidelberg, Germany)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00105-025-05554-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

皮肤红斑狼疮(CLE)包括异质谱的自身免疫性皮肤病。主要有四种类型:急性(CLE),亚急性(SCLE),中期(ICLE)和慢性CLE (CCLE)。流行病学研究表明,在CLE诊断后的前3年内,发生系统性红斑狼疮(SLE)的总体风险最高。因此,新诊断CLE的患者应密切监测全身症状,特别是在CLE诊断后的头几年。CLE的治疗包括局部治疗和全身治疗。有器官和皮肤表现的SLE的治疗最好与内科风湿病专家密切合作。红斑狼疮的整体治疗景观越来越趋向个性化的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Lupus erythematosus].

Cutaneous lupus erythematosus (CLE) comprises a heterogeneous spectrum of autoimmune dermatoses. Four main forms are distinguished: acute (ACLE), subacute (SCLE), intermediate (ICLE), and chronic CLE (CCLE). Epidemiological studies show that the overall risk of developing systemic lupus erythematosus (SLE) is highest within the first 3 years following diagnosis of CLE. Therefore, patients with newly diagnosed CLE should be closely monitored for systemic symptoms, especially in the first few years following CLE diagnosis. Therapy of CLE includes both topical and systemic approaches. Treatment of SLE with organ and cutaneous manifestation should ideally be treated in close cooperation with an internal medicine rheumatologist. The overall therapeutic landscape of lupus erythematosus in increasingly moving toward personalized approaches.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信